Advisory: Give yourself extra time when travelling by car to Toronto General Hospital, Princess Margaret Cancer Centre, or Toronto Rehab University Centre. City of Toronto construction on University Ave. may cause delays.
At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Dr. Karun Singh received the Canadian Association for Neuroscience’s Young Investigator Award in 2018
With sophisticated gene editing tools, Dr. Karun Singh is investigating how genes influence neurological development and vision
One of the key roadblocks to treating neurodevelopmental disorders (NDDs) such as autism, schizophrenia or Down syndrome is understanding the root causes of the conditions.
Dr. Karun Singh is on a mission to overcome these hurdles by leveraging the power of stem cells and gene editing technology, with the goal of developing effective treatments – or even cures – for NDDs. It's a daunting task, but one the neuroscientist relishes, especially because he has the opportunity to bring hope to families of children with NDDs.
"I interact with families all the time, and the thing I tell them is that they're taking part in the latest and most emerging research," says Dr. Singh, a newly recruited senior scientist at the Donald K. Johnson Eye Institute. "When we can use a stem cell-based approach, it really is a more accurate way to study their disorder."
Simply put, NDDs impair development in the brain, resulting in everything from learning disabilities to visual impairment. Scientists have struggled to study these disorders because they can't access live patient brain tissue, limiting their research capabilities.
Dr. Singh's groundbreaking work focuses on understanding how genes and genetic mutations influence neurological development. By lab-engineering brain cells from patient stem cells using sophisticated gene editing tools, he's able to study neurological conditions in a more comprehensive way.
He and his team can take a blood sample from an individual with a specific brain disorder, then mimic what's happening in the person's brain in a controlled laboratory setting, without invasive testing.
"Many of the brain development disorders that we study are caused by genetic mutations," explains Dr. Singh, who joined UHN in June 2020, after earning accolades for his work at the Stem Cell and Cancer Research Institute at McMaster University in Hamilton. "We try to model that [genetic defect] in the lab by creating stem cells from the person's blood and then recreating their brain tissue in a dish."
Dr. Singh is using the same approach to model eye tissue in the lab, gaining insight into the visual impairment caused by NDDs and the development of vision disorders like macular degeneration.
He explains that once they understand the molecular dysfunction happening in the brain, they can find an already–approved drug which targets that particular molecular dysfunction and might correct the deficiency.
"If it's a different drug that's normally used to treat cancer, for example, we can repurpose it for this neurological brain development disorder caused by a genetic defect," says Dr. Singh.
"In order to know which drug to choose, you have to know, at the molecular level, what's wrong.